Inventors:
Jeroen Aerssens - Nieuwrode (Holsbeek), BE
Gregory Charles Fanning - Woluwe St Pierre (Brussels), BE
Michael W. Fried - Chapel Hill NC, US
Assignee:
Janssen R&D Ireland - Eastgate
International Classification:
C12Q 1/68, G06G 7/60, G01N 33/566, C12Q 1/70, C40B 30/04
US Classification:
506 9, 435 5, 435 611, 436501, 703 11
Abstract:
The current invention relates to a method of combining IL28B genotype determination with pre-treatment serum level measurement of IP-10 to predict the outcome of a sustained virological response (SVR) or non-response to peginterferon and ribavirin for individual patients infected with HCV.